These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2489 related items for PubMed ID: 18056932

  • 1. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C.
    Am J Health Syst Pharm; 2007 Dec 15; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [Abstract] [Full Text] [Related]

  • 2. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C.
    J Manag Care Pharm; 2007 Oct 15; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [Abstract] [Full Text] [Related]

  • 3. New strategies in controlling drug resistance.
    Frame D.
    J Manag Care Pharm; 2007 Oct 15; 13(8 Suppl A):13-7. PubMed ID: 17970610
    [Abstract] [Full Text] [Related]

  • 4. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP, Croom KF, Goa KL.
    BioDrugs; 2004 Oct 15; 18(3):207-10. PubMed ID: 15161340
    [Abstract] [Full Text] [Related]

  • 5. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM.
    Leukemia; 2008 Jun 15; 22(6):1200-6. PubMed ID: 18401416
    [Abstract] [Full Text] [Related]

  • 6. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL.
    Clin Ther; 2012 Feb 15; 34(2):272-81. PubMed ID: 22285209
    [Abstract] [Full Text] [Related]

  • 7. New strategies in controlling drug resistance in chronic myeloid leukemia.
    Frame D.
    Am J Health Syst Pharm; 2007 Dec 15; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
    [Abstract] [Full Text] [Related]

  • 8. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
    Jabbour E, Kantarjian H.
    Am J Hematol; 2012 Nov 15; 87(11):1037-45. PubMed ID: 23090888
    [Abstract] [Full Text] [Related]

  • 9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M.
    Clin Ther; 2007 Nov 15; 29(11):2289-308. PubMed ID: 18158072
    [Abstract] [Full Text] [Related]

  • 10. Loss of response to imatinib: mechanisms and management.
    Shah NP.
    Hematology Am Soc Hematol Educ Program; 2005 Nov 15; ():183-7. PubMed ID: 16304378
    [Abstract] [Full Text] [Related]

  • 11. Imatinib: a review of its use in chronic myeloid leukaemia.
    Moen MD, McKeage K, Plosker GL, Siddiqui MA.
    Drugs; 2007 Nov 15; 67(2):299-320. PubMed ID: 17284091
    [Abstract] [Full Text] [Related]

  • 12. Targeted drugs in chronic myeloid leukemia.
    Gora-Tybor J, Robak T.
    Curr Med Chem; 2008 Nov 15; 15(29):3036-51. PubMed ID: 19075651
    [Abstract] [Full Text] [Related]

  • 13. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D.
    Ther Umsch; 2006 Apr 15; 63(4):249-54. PubMed ID: 16689455
    [Abstract] [Full Text] [Related]

  • 14. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
    Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M.
    Blood; 2007 May 15; 109(10):4143-50. PubMed ID: 17264298
    [Abstract] [Full Text] [Related]

  • 15. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
    Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP.
    Blood; 2007 Mar 15; 109(6):2303-9. PubMed ID: 17138817
    [Abstract] [Full Text] [Related]

  • 16. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ, Zhang S, Liu XL.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb 15; 16(1):217-21. PubMed ID: 18315935
    [Abstract] [Full Text] [Related]

  • 17. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG, Holyoake TL.
    Biochem Soc Trans; 2007 Nov 15; 35(Pt 5):1347-51. PubMed ID: 17956348
    [Abstract] [Full Text] [Related]

  • 18. First-line therapy for chronic myeloid leukemia: Past, present, and future.
    Pavlovsky C, Kantarjian H, Cortes JE.
    Am J Hematol; 2009 May 15; 84(5):287-93. PubMed ID: 19306355
    [Abstract] [Full Text] [Related]

  • 19. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
    Li J, Xu G, Yu S, He L, Guo L.
    J Int Med Res; 2011 May 15; 39(2):337-47. PubMed ID: 21672337
    [Abstract] [Full Text] [Related]

  • 20. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.
    N Engl J Med; 2006 Jun 15; 354(24):2531-41. PubMed ID: 16775234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 125.